Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.

Norah L Henry Mark R Somerfield Zoneddy Dayao Anthony D EliasKevin KalinskyLisa Meier McShaneBeverly MoyBen Ho ParkKelly M ShanahanPriyanka SharmaRebecca ShatskyErica M Stringer-ReasorMelinda TelliNicholas C Turner Angela M DeMichele

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

mutations, for homologous recombination deficiency, or for TROP2 expression to guide MBC therapy selection. There are insufficient data to recommend routine use of ctDNA or circulating tumor cells to monitor response to therapy among patients with MBC.Additional information can be found at www.asco.org/breast-cancer-guidelines.

Keyphrases

circulating tumor cells
metastatic breast cancer
dna damage
poor prognosis
dna repair
clinical practice
stem cells
circulating tumor
electronic health record
machine learning
young adults
oxidative stress
big data
cell therapy
health information